Advertorial

Charles River Laboratories announces new tumour model compendium

Posted: 28 February 2018 | | No comments yet

The Compendium provides scientists an online resource to help design efficient in vitro and in vivo oncology research studies.

device

 Charles River Laboratories International, Inc. recently announced the launch of its new online Tumour Model Compendium web interface. The new Compendium interface provides oncology researchers with an easily accessible, user-friendly resource to identify tumour models based on specific molecular and histological properties, accompanied by selected patient information.

Charles River’s Compendium provides access to a comprehensive collection of well-established tumour models for early-stage oncology research. The collection includes tumour models from a wide range of tumour subtypes for both in vivo and in vitro oncology research, including patient-derived xenografts (PDXs), cell line-derived xenografts (CDX), and syngeneic models. These resources allow researchers to easily identify the most appropriate tumour models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.

Dedication to Immuno-oncology

The most recent Compendium update expands existing content to include human leukocyte antigen (HLA) subtyping data. As the immuno-oncology industry shifts toward increasingly more personalised therapies, the availability of HLA data helps researchers understand and control immune system variability, leading to increased study efficacy and efficiency.

The Compendium is just one example of Charles River’s commitment to developing a robust offering of immuno-oncology services. In January 2018, the Company announced its acquisition of KWS BioTest, adding significant expertise in immunology to its existing portfolio.

In Vitro Oncology Services

Additionally, the Compendium now includes new molecular data for a large proportion of its proprietary and commercial cell lines, making it a valuable resource for in vitro oncology research. In vitro oncology has emerged as an industry standard for early toxicity and patient identification, allowing researchers to test the efficacy of compound in a rapid, reliable, and cost-effective way.

The Company has also partnered with OcellO and InSphero AG to leverage 3D cell culture technology with its existing in vitro oncology platforms. Charles River has more than 450 well-characterised, proprietary PDXs in its portfolio, which represent all major tumour histotypes, and provide extensive background and characterisation for oncology research. To learn more about Charles River’s oncology research capabilities, visit www.criver.com.

Send this to a friend